PierianDx is launching clinical interpretation as part of its next-generation sequencing services portfolio.
Customers will be able to select from a menu of options.
Variant scientist review, conducted by PierianDx cancer biologists and genetics professionals, will provide variant classification and annotation.
Medical director review, conducted by board-certified molecular pathologists and medical geneticists, will provide assessments of variants' medical significance, including recommended therapeutic options, disease monitoring, clinical trial enrollment, or genetic counseling. Options for direct consultation or participation on molecular tumor boards are also available.
Sign-out services, conducted by PierianDx medical directors with the appropriate state licensures, will provide sign-out for cases previously reviewed by interpretation services.